Enara Health’s Post

💤 Big news: Zepbound® (tirzepatide) is now FDA-approved to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Here’s the scoop: 1️⃣ Fewer Disruptions: Zepbound cut breathing interruptions by 25/hour—5x better than placebo. With PAP therapy, this number went up to 29 fewer interruptions per hour! 2️⃣ Major Weight Loss: Participants lost up to 20% body weight (~50 lbs) in one year. 3️⃣ No More Symptoms: Nearly 50% had no OSA symptoms after one year. Zepbound’s results are incredible, but real change requires lifestyle adjustments too. Remember, medication works best when combined with sustainable habits for long-term health! 💡 🔗 Read more: https://lnkd.in/eFTFYMbD #SleepApnea #Obesity #Treatment #Zepbound #GLP1 #OSA #Sleep #Snoring #Weight #Tirzepatide #Mounjaro #Zepbound #WeightLoss #Medication #Lifestyle #Science #Research FDA

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics